Combined platelet transfusion for treating blood disorders
Combined Platelet Transfusion:A Single-arm, Open, Prospective, Non-inferiority Clinical Trial
This study is testing if a new way of giving platelet transfusions can help people with blood disorders when regular options aren't available.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 86 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | The General Hospital of Western Theater Command Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06613425 on ClinicalTrials.gov |
What this trial studies
This clinical study investigates the effectiveness of combined platelet transfusion in patients with hematologic diseases who require platelet therapy. It is a single-arm, open-label, prospective study that aims to provide ABO-compatible transfusions when standard options are unavailable. Patients will be enrolled over a 15-month period, followed by a 6-month treatment phase and a 3-month follow-up. The study focuses on ensuring safety and efficacy in transfusion practices to minimize adverse reactions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 with hematologic diseases requiring platelet transfusion.
Not a fit: Patients who do not require platelet transfusions or have contraindications for transfusion therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the safety and availability of platelet transfusions for patients with blood disorders.
How similar studies have performed: While there is limited data on combined platelet transfusions, similar approaches in transfusion medicine have shown promise in improving patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Aged 18-65 years; 2. Disease treatment in the research hospital; 3. Applied for platelet transfusion therapy. Exclusion Criteria: * 1\. One month before the start of this study, he participated in other clinical trials of drugs and instruments related to platelet transfusion efficacy; 2. Without platelet transfusion indications; 3. Only received platelet transfusion in the outpatient department and left the hospital without efficacy evaluation after transfusion; 4. Gave up platelet transfusion therapy for any reason after enrollment; 5. Transferred or discharged from hospital for any reason before platelet transfusion after enrollment; 6. Did not receive combined platelet transfusion during the 6-month treatment period after enrollment
Where this trial is running
Chengdu, Sichuan
- Li Zhang — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Principal investigator: zhang li — The General Hospital of Weastern Theater Command
- Study coordinator: zhang li
- Email: 1062747632@qq.com
- Phone: +86 13982283001
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.